InsiderTrades

Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.

Accepted 2022-08-10 00:00:00 ET · period of report 2022-08-09 · accession 0001104659-22-088700 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-08-10 2022-08-09 SUPN Khattar Jack A. Pres, CEO, Dir M - OptEx $0.00 +63.1K 764.4K +9% $0
D 2022-08-10 2022-08-09 SUPN Khattar Jack A. Pres, CEO, Dir S - Sale+OE $31.15 -39.4K 725.0K -5% -$1.23M
D 2022-08-10 2022-08-09 SUPN Khattar Jack A. Pres, CEO, Dir M - OptEx $0.00 -63.1K 44.9K -58% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-08-09 M A 63,100 $0.00 764,409 D — — (F1) Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.
2 Common Common Stock 2022-08-09 S D 39,431 $31.15 724,978 D — — (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.64, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. (F1) Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.
3 Derivative Employee Stock Option (Right to Buy) 2022-08-09 M D 63,100 $0.00 44,900 D $7.90 · — to 2023-02-05 63,100 Common Stock (F4) The option vested in four equal annual installments beginning on February 5, 2014.